CN101336250A - 多肽 - Google Patents

多肽 Download PDF

Info

Publication number
CN101336250A
CN101336250A CNA2006800523510A CN200680052351A CN101336250A CN 101336250 A CN101336250 A CN 101336250A CN A2006800523510 A CNA2006800523510 A CN A2006800523510A CN 200680052351 A CN200680052351 A CN 200680052351A CN 101336250 A CN101336250 A CN 101336250A
Authority
CN
China
Prior art keywords
egfr
binding polypeptide
ala
glu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800523510A
Other languages
English (en)
Chinese (zh)
Inventor
F·尼尔森
T·埃里克松
A·荣森
S·斯托尔
M·弗里德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Priority to CN201310114471.0A priority Critical patent/CN103288935B/zh
Publication of CN101336250A publication Critical patent/CN101336250A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2006800523510A 2005-12-05 2006-12-05 多肽 Pending CN101336250A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310114471.0A CN103288935B (zh) 2005-12-05 2006-12-05 多肽

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0524788.7A GB0524788D0 (en) 2005-12-05 2005-12-05 Polypeptides
GB0524788.7 2005-12-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310114471.0A Division CN103288935B (zh) 2005-12-05 2006-12-05 多肽

Publications (1)

Publication Number Publication Date
CN101336250A true CN101336250A (zh) 2008-12-31

Family

ID=35686099

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800523510A Pending CN101336250A (zh) 2005-12-05 2006-12-05 多肽
CN201310114471.0A Expired - Fee Related CN103288935B (zh) 2005-12-05 2006-12-05 多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310114471.0A Expired - Fee Related CN103288935B (zh) 2005-12-05 2006-12-05 多肽

Country Status (9)

Country Link
US (3) US8247375B2 (enExample)
EP (2) EP2431383B1 (enExample)
JP (2) JP5898826B2 (enExample)
CN (2) CN101336250A (enExample)
CA (1) CA2631430C (enExample)
DK (1) DK2431383T3 (enExample)
ES (1) ES2599996T3 (enExample)
GB (1) GB0524788D0 (enExample)
WO (1) WO2007065635A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064235A (zh) * 2015-01-12 2018-05-22 阿菲博迪公司 Il-17a结合多肽
CN117106035A (zh) * 2023-10-25 2023-11-24 烟台药物研究所 一种肿瘤靶向多肽、多肽偶联药物及制备与应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
GEP20156390B (en) * 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
JP5677943B2 (ja) 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
JP5960598B2 (ja) * 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
EA024507B1 (ru) 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
JP5812303B2 (ja) * 2011-06-03 2015-11-11 国立研究開発法人産業技術総合研究所 酸性域での親和性が低下したプロテインａ変異型タンパク質及び抗体捕捉剤
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
TWI443108B (zh) 2011-12-28 2014-07-01 Ind Tech Res Inst 抗人類表皮生長因子受體抗體及其應用
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
KR102191655B1 (ko) 2012-10-05 2020-12-16 애피바디 에이비 Her3 결합 폴리펩티드
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
EP3575312A1 (en) 2014-01-27 2019-12-04 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
SI3604333T1 (sl) 2014-03-11 2021-08-31 Molecular Templates, Inc. Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38
ES2723774T3 (es) 2014-03-11 2019-09-02 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
KR20170074243A (ko) 2014-10-31 2017-06-29 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 변형된 t 세포의 생성 방법 및 조성물
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
US10521754B2 (en) * 2016-03-08 2019-12-31 Auctane, LLC Concatenated shipping documentation processing spawning intelligent generation subprocesses
CN111925425B (zh) * 2020-08-12 2023-03-10 天津科技大学 甲胎蛋白特异性结合多肽及应用
JP2025507294A (ja) 2022-02-04 2025-03-18 ザイトックス セラピューティクス アクチボラゲット Ｅｇｆｒ結合ドメインとマスキングドメインとを含む融合タンパク質
KR20250047787A (ko) 2022-08-10 2025-04-04 교와 가부시키가이샤 어피바디 미셀 약물 복합체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
SE9901379D0 (sv) * 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
SE0301936D0 (sv) 2003-06-30 2003-06-30 Affibody Ab New polypeptide
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
EP1731523A4 (en) * 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINDERIVAT
DE05733048T1 (de) 2004-04-06 2007-05-10 Affibody Ab Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung
US20070172901A1 (en) 2004-04-16 2007-07-26 Hidetoshi Okabe Method for the evaluation of the functional status of the growth factor receptor protein expressed in malignant tumors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064235A (zh) * 2015-01-12 2018-05-22 阿菲博迪公司 Il-17a结合多肽
CN117106035A (zh) * 2023-10-25 2023-11-24 烟台药物研究所 一种肿瘤靶向多肽、多肽偶联药物及制备与应用
CN117106035B (zh) * 2023-10-25 2024-04-23 烟台药物研究所 一种肿瘤靶向多肽、多肽偶联药物及制备与应用

Also Published As

Publication number Publication date
US20140178301A1 (en) 2014-06-26
ES2599996T3 (es) 2017-02-06
US8598113B2 (en) 2013-12-03
CA2631430C (en) 2017-03-07
EP2431383B1 (en) 2016-09-28
WO2007065635A1 (en) 2007-06-14
JP5898826B2 (ja) 2016-04-06
GB0524788D0 (en) 2006-01-11
EP2431383A1 (en) 2012-03-21
JP2014087361A (ja) 2014-05-15
CA2631430A1 (en) 2007-06-14
JP2009519013A (ja) 2009-05-14
CN103288935B (zh) 2017-11-17
EP1973934B1 (en) 2014-11-05
US9107965B2 (en) 2015-08-18
DK2431383T3 (en) 2017-01-09
US20090016957A1 (en) 2009-01-15
US20130005653A1 (en) 2013-01-03
EP1973934A1 (en) 2008-10-01
US8247375B2 (en) 2012-08-21
CN103288935A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
CN103288935B (zh) 多肽
Friedman et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor
AU2004253835B2 (en) Polypeptides having binding affinity for HER2
CN109879957A (zh) 针对prame的高亲和力t细胞受体
EP2904013B1 (en) Her3 binding polypeptides
Liu et al. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A
Leitao et al. Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity
US20250215093A1 (en) Fusion protein comprising an egfr-binding domain and a masking domain
WO2014076177A1 (en) New polypeptide
HK1125657A (zh) 多肽
HK1186197A (en) Polypeptides
HK1186197B (zh) 多肽
Quan et al. Imaging tumor endothelial marker 8 using an 18F-labeled peptide
HK1207657B (en) Her3 binding polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125657

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125657

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20081231